linjc16/ctgov huggingface dataset:
Procalcitonin in Cirrhotic Patients at High Risk for Sepsis

Study Overview
=================
Brief Summary
-----------------
Infections are frequent life-threatening events in patients with cirrhosis, occurring at least in 35% of hospitalized patients and accounting for 20% of inpatients death. Among cirrhotics, ascitic patients have the highest risk of death for sepsis. At the admission, no clear-cut clinical and biochemical features are helpful in diagnosing and prognostically stratifying those patients with sepsis. Procalcitonin (PCT)is a breakthrough marker presenting high sensibility and specificity in diagnosing bacterial infections in different clinical settings. The purpose of this study is to evaluate PCT as a diagnostic and prognostic tool for sepsis in hospitalized cirrhotic patients with ascitic decompensation.

Official Title
-----------------
Role of Procalcitonin (PCT) for the Diagnosis of Sepsis in Ascitic Cirrhotic Patients

Conditions
-----------------
Cirrhosis, Ascites, Sepsis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: liver cirrhosis regardless of aetiology clinically relevant ascitic decompensation at time of hospital admission Exclusion Criteria: high haematic ascites ongoing antimicrobial therapy or stopped less than 7 days before admission last hospital discharge within 7 days surgery or trauma within 30 days from enrolment hepatocellular carcinoma out of Milan criteria extra hepatic malignancies immunodeficiency syndrome pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Decompensated cirrhotic patients<br>Cirrhotic patients presenting with clinically detectable ascites (Grade 2 o Grade 3) | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cirrhosis, Ascites, Decompensation, Bacterial infection, Sepsis, Procalcitonin, PCT
Single IV Dose of GLYX-13 in Patients With Treatment-Resistant Depression

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether GLYX-13 reduces depression score in patients with treatment-resistant depression.

Official Title
-----------------
Randomized, Double Blind, Placebo Controlled, Single IV Dose Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder

Conditions
-----------------
Major Depressive Disorder

Intervention / Treatment
-----------------
* Drug: GLYX-13


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: diagnosis of major depressive disorder consistent with DSM-IV-TR current episode greater than 8 weeks in duration Hamilton Depression score >/- 21 less than 25% reduction in depression during current episode assessed by ATRQ Exclusion Criteria: Axis diagnosis of other psychiatric disorders Experiencing hallucinations, delusions, other psychotic symptomatology ECT during current episode

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: Normal Saline<br>IV placebo | Drug: GLYX-13<br>* single IV dose<br>* Other names: ThrProProThr;|
| Experimental: GLYX-13, 1 mg/kg<br> | Drug: GLYX-13<br>* single IV dose<br>* Other names: ThrProProThr;|
| Experimental: GLYX-13, 5 mg/kg<br> | Drug: GLYX-13<br>* single IV dose<br>* Other names: ThrProProThr;|
| Experimental: GLYX-13, 10 mg/kg<br> | Drug: GLYX-13<br>* single IV dose<br>* Other names: ThrProProThr;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in depression score |  | 14 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in BPRS+ |  | 14 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
depression, NMDA antagonist, treatment resistant
Safety/Efficacy of Systane Free vs Refresh Tears

Study Overview
=================
Brief Summary
-----------------
The objective of this study is to evaluate the safety and efficacy of Systane Free FID 105783 in comparison to Refresh Tears Lubricant Eye Drops (Allergan) in a specified population of dry eye patients.

Official Title
-----------------
An Evaluation of the Safety and Efficacy of Systane Free FID 105783 - II

Conditions
-----------------
Dry Eye

Intervention / Treatment
-----------------
* Drug: Systane Free Lubricant Eye Drops


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: > = 3 stain using NEI grid and need artificial tears at least some of the time.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Systane Free Lubricant Eye Drops|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Corneal Staining change from baseline |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Comfort, Conjunctival Staining |  |  |
Risk Factors for Aneurysm Rebleeding

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to examine the risk factors for aneurysm rebleeding.

Detailed Description
-----------------
To investigate risk factors for spontaneous aneurysm rebleeding during hospitalization and to reach conclusions if any,of clinical signs for predicting rebleeding.

Official Title
-----------------
Risk Factors in Predicting Spontaneous Intracranial Aneurysm Rebleeding During Hospitalization

Conditions
-----------------
Subarachnoid Hemorrhage, Aneurysmal

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Individual whose clinical course was clear enough to be traced back and whose conservative treatment duration was shorter than 6 weeks was included Exclusion Criteria: Rebleeding patients with certain inducing factors such as: severe emotional episode, severe coughing, constipation, excessive activities, or with coagulation disorder,or with other intracranial vascular malformations,such as: moyamoya disease, arteriovenous malformation were excluded. Also patients who rebled while angiography were excluded.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| the case group<br>The case group referred to SAH patients with aneurysm rebleeding | |
| the control group<br>the control group referred to SAH patients not with aneurysm rebleeding | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Aneurysm rebleeding |  | up to 7 months |
The Effect of Luteinizing Hormone (LH) Supplementation Following Gonadotropin-releasing Hormone (GnRH) Antagonist Administration in Advanced Reproductive Ageing Women Undergoing IVF and Embryo Transfer (IVF/ET)

Study Overview
=================
Brief Summary
-----------------
To explore whether recombinant LH (rLH) supplementation (Leuveris) to recombinant follicle stimulating hormone (rFSH) following GnRH antagonist treatment has an advantage in infertile women with advanced reproductive ageing undergoing IVF-ET.

Conditions
-----------------
Pregnancy Result Rape

Intervention / Treatment
-----------------
* Drug: Leuveris
* Drug: Leuveris


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: female candidate to IVF between 30-45 years old Exclusion Criteria: not included for fertilization

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 60 infertile women<br>Candidates for IVF-ET treatment | Drug: Leuveris<br>* IV<br>Drug: Leuveris<br>* All recruited women will be treated similarly employing the recombinant FSH and the fixed GnRH antagonist. Concomitantly, on the same day of the antagonist administration r-LH will be administered daily and continued until human chorionic gonadotropin (hCG) day.<br>|
| No Intervention: control<br>no treatment | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pregnancy rate |  | Starting February 2010 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Fertilization rate |  | Starting February 2010 till April 2013 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
pregnancy, IVF
Model 4195 Left Ventricular (LV) Lead Chronic Performance Study

Study Overview
=================
Brief Summary
-----------------
Evaluate long-term performance of the 4195 LV Lead. This evaluation is based on the number of lead-related complications occuring during the study compared to the number of leads enrolled in the study. The leads will be followed for 5 years after implant. This study is required by FDA as a condition of approval of the Model 4195 LV Lead and is integrated within Medtronic's post-market surveillance platform.

Detailed Description
-----------------
Model 4195 LV lead complication-free survivability will be summarized.

Official Title
-----------------
Attain StarFix® Model 4195 Left Ventricular Lead Chronic Performance Post Approval Study

Conditions
-----------------
Heart Failure

Participation Criteria
=================
Eligibility Criteria
-----------------
Patients who meet all of the following inclusion criteria and do not meet any of the following exclusion criteria are eligible for enrollment. Inclusion Criteria Patient or legally authorized representative provides written authorization and/or consent per institution and geographical requirements Patient has or is intended to receive an Attain StarFix Model 4195 LV lead Patient within 30 day post implant enrollment window Exclusion Criteria Patient who is, or is expected to be inaccessible for follow-up Patient with exclusion criteria required by local law Patient is currently enrolled in or plans to enroll in any concurrent drug and/or device study that may confound results
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Lead-related complication rate. |  | Implant to 5 years post-implant. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Types of Model 4195 lead-related events |  | 5 years post implant |
High(Deadlift) Versus Low Intensity Motor Control Exercises on Low Back Pain

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to evaluate and compare the effects of high-intensity (deadlift) versus low-intensity motor control exercises on selfrated pain, function and symptoms on patients with peripherally mediated pain

Official Title
-----------------
Effects of High(Deadlift) Versus Low Intensity Motor Control Exercises on Patients With Peripherally Mediated Low Back Pain

Conditions
-----------------
Low Back Pain

Intervention / Treatment
-----------------
* Procedure: High intensity motor control exercise (deadlift)
* Procedure: Low intensity motor control exercise


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: low back pain over 3 month the pain must originate locally from the lowe back and be nociceptive Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: High intensity motor control exercise (deadlift)|12 treatment sessions over a 8 week period is planned for the high intensity motor control exercise.|
|Procedure: Low intensity motor control exercise|12 sessions of low intensity motor control exercises over 8 weeks|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Selfrated function, symptoms and pain-rating |  | 8 weeks, 6 month, 12 month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Functional capacity |  | 8 weeks, 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
deadlift, motor control, exercises, pain, function, functional capacity
Effects of HTEA ON Heart Failure Secondary to Idiopathic Dilated Cardiomyopathy or Post-myocardial Infarction

Study Overview
=================
Brief Summary
-----------------
The investigators would evaluate the effects of the novel method, HTEA on cardiac function in the heart failure patients secondary to idiopathic dilated cardiomyopathy and post-myocardial infarction.

Detailed Description
-----------------
The investigators would evaluate the effects of the novel method, HTEA on cardiac function in the heart failure patients secondary to idiopathic dilated cardiomyopathy and post-myocardial infarction. The specific index is 6 miniutes walk distance, echocardiography, NYHA, NTproBNP level, peripherial WBC, RBC, PLT, Cre, UA, K+, Na+ upon entrance to hospital and 4 weeks after HTEA treatment, and 3 months after discharge. The morbidity and re-hospitalization would also calculated 3 months after discharge.

Official Title
-----------------
Effects of HTEA ON Heart Failure Secondary to Idiopathic Dilated Cardiomyopathy or Post-myocardial Infarction

Conditions
-----------------
Congestive Heart Failure

Intervention / Treatment
-----------------
* Drug: HTEA


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 90 chronic cardiac failure patients in our hospital were selected and divided into two groups. Exclusion Criteria: Vavular diseases

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| idiopathic dilated cardiomyopathy group<br>idiopathic dilated cardiomyopathy group treated with HTEA | Drug: HTEA<br>* HTEA<br>|
| post-myocardial infarction group<br>post-myocardial infarction group treated with TEA | Drug: HTEA<br>* HTEA<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Morbidity |  | 1 months to 3 months after discharge | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The decreased degree of NT-proBNP higher than 30% |  | 3 months after discharge |
Prevalence of Perimyocarditis After Covid-19 Vaccine

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to determine whether there is a higher prevalence of perimyocarditis after undergoing vaccination for Covid-19.

Official Title
-----------------
Prevalence of Perimyocarditis After Covid-19 Vaccine

Conditions
-----------------
Perimyocarditis, Covid19

Intervention / Treatment
-----------------
* Diagnostic Test: Laboratory Blood Tests
* Diagnostic Test: ECG
* Diagnostic Test: PCR
* Diagnostic Test: Antibody test
* Diagnostic Test: Echocardiography
* Diagnostic Test: MRI


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients planning Pfizer-BioNTech BNT162b2 vaccination against Covid19 Exclusion Criteria: Patients infected with Covid19

Ages Eligible for Study
-----------------
Minimum Age: 16 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Covid19 Vaccinated Patients<br>Patients who are planning to receive Pfizer-BioNTech BNT162b2 vaccines against Covid19 | Diagnostic Test: Laboratory Blood Tests<br>* Blood tests to determine liver and kidney functioning, total blood count, and troponin levels<br>Diagnostic Test: ECG<br>* ECG to determine heart rate and functioning<br>Diagnostic Test: PCR<br>* PCR test to determine whether patient has Covid19<br>Diagnostic Test: Antibody test<br>* Antibody test to determine level of antibodies to Covid19<br>Diagnostic Test: Echocardiography<br>* If Troponin level elevated echocardiography to determine heart function<br>Diagnostic Test: MRI<br>* If Troponin level elevated MRI to determine heart function<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Elevated Troponin | Laboratory blood tests will be taken before and after Covid19 vaccination and compared. Troponin levels above normal range of 0.4 ng/ml will indicate possibility of perimyocarditis and patient will referred for additional testing. | 4 weeks |
Seroepidemiology of Viral Hepatitis in Hong Kong

Study Overview
=================
Brief Summary
-----------------
Immunisation policies have strong influences on the epidemiology of hepatitis A and B infection. In Hong Kong, vaccines against both viruses have been available through different channels and programmes in the past 3 decades. To evaluate the changes in the prevalence of hepatitis A and B in the general population, a seroepidemiology study is conducted involving a prospective cross-sectional survey followed for serology testing. Eligible members of 1327 spatially random households would be invited to join the study by completing a questionnaire and providing blood samples, either by dried blood spots or venesection, for determining the presence of antigen and/or antibody against hepatitis B, as well as antibody against hepatitis A. The main measures comprise a set of metrics on the prevalence of hepatitis A and B. Analysis would be conducted to examine the association of risk factors with the tested markers and describe the attitudes towards viral hepatitis vaccination. The results would allow us to understand the transmission potential of hepatitis A and B in the community would be influenced by the changing disease epidemiology and coverage of vaccination, which inform the development of new vaccination strategies in Hong Kong

Official Title
-----------------
Evaluation of the Seroepidemiology of Hepatitis A and B in the General Population for Informing the Development of New Hepatitis Vaccination Strategies in Hong Kong

Conditions
-----------------
Viral Hepatitis

Intervention / Treatment
-----------------
* Other: No intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: residents normally living in Hong Kong living in domestic households randomly selected from Building Groups Any age, while subjects below the age of 18 would require informed consent of their guardians for participation Any gender Exclusion Criteria: unable to understand written Chinese or English, failure to give consent for participation living in institution or non-domestic housing, foreign domestic helpers, normally living in Hong Kong
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: No intervention|Blood samples will be collected from recruited subjects from invited households for testing for hepatitis B (HBsAg, anti-HBs and anti-HBc) and hepatitis A (anti-HAV)|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| hepatitis B infection prevalence | Proportion of individuals with positive HBsAg | 12 months | 
| hepatitis A immunity prevalence | Proportion of individuals with positive IgG against HAV | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
hepatitis A, hepatitis B, epidemiology